Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Preparation of Thermosensitive Gel for Controlled Release of Levofloxacin and Their Application in the Treatment of Multidrug-Resistant Bacteria

Full text
Alves, Danilo Antonini ; Machado, Daisy ; Melo, Adriana ; Carneiro Pereira, Rafaella Fabiana ; Severino, Patricia ; de Hollanda, Luciana Maria ; Araujo, Daniele Ribeiro ; Lancellotti, Marcelo
Total Authors: 8
Document type: Journal article
Web of Science Citations: 1

Levofloxacin is a synthetic broad-spectrum antibacterial agent for oral or intravenous administration. Chemically, levofloxacin is the levorotatory isomer (L-isomer) of racemate ofloxacin, a fluoroquinolone antibacterial agent. Quinolone derivatives rapidly and specifically inhibit the synthesis of bacterial DNA. Levofloxacin has in vitro activity against a broad range of aerobic and anaerobic Gram-positive and Gram-negative bacteria. However, formulation of combined poloxamers thermoregulated (as Pluronic (R) F127) and levofloxacin for use in multiresistant bacterial treatment were poorly described in the current literature. Thus, the aim of the present work is to characterize poloxamers for levofloxacin controlled release and their use in the treatment of multidrug bacterial resistance. Micelles were produced in colloidal dispersions, with a diameter between 5 and 100 nm, which form spontaneously from amphiphilic molecules under certain conditions as concentration and temperature. Encapsulation of levofloxacin into nanospheres showed efficiency and enhancement of antimicrobial activity against Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae when compared with only levofloxacin. Furthermore, all formulations were not cytotoxic for NIH/3T3 cell lineage. In conclusion, poloxamers combined with levofloxacin have shown promising results, better than alone, decreasing the minimal inhibitory concentration of the studied bacterial multiresistance strains. In the future, this new formulation will be used after being tested in animal models in patients with resistant bacterial strains. (AU)

FAPESP's process: 11/21822-3 - Mechanisms of antibiotic resistance aquisition by bacteria causing infection of human urinary tract - a farmacogenomic and biopharmaceutic design
Grantee:Danilo Antonini Alves
Support type: Scholarships in Brazil - Doctorate
FAPESP's process: 11/21685-6 - Mechanisms of antibiotic resistance aquisition by bacteria causing infection of human urinary tract: a farmacogenomic and biopharmaceutic design
Grantee:Marcelo Lancellotti
Support type: Regular Research Grants
FAPESP's process: 14/14457-5 - Lipid-based nanocarriers (SLN/NLC and remote-loading liposomes) used to improve the upload and potency of local anesthetics
Grantee:Eneida de Paula
Support type: Research Projects - Thematic Grants